The present disclosure provides compositions and methods for treatment of bladder cancer. The methods include administering an immunoconjugate having a binding protein that specifically binds to Ep-CAM and a toxin to a subject in need of treatment for bladder cancer. In one aspect, the present disclosure provides methods for treating bladder cancer in a subject in need thereof, wherein the methods comprise administering to the subject an immunoconjugate, and wherein the administration is sufficient to result in event-free survival of the subject. In some embodiment's, the administration is sufficient to result in event-free survival of the subject for at least 12 months following the first dose of the the immunoconjugate. In some embodiment's, the administration is sufficient to result in event free survival of the subject for at least about 18 months following the first dose of the immunoconjugate.
